Douglas Alan Lorenz

USPTO Granted Patents = 25 (Patent Applications = 10)

CIPO Patents = 1 (Patent Applications = 1)

EPO Patents = 9 (Patent Applications = 5)

Average Co-Inventor Count = 4.9

ph-index = 5

Forward Citations = 74(Granted Patents)

Company Filing History:

Medivation Prostate Therapeutics, Inc.

patents

6. 2 out of 43

Cymabay Therapeutics, Inc.

patents

7. 1 out of 832,680

Other

patents

where one patent can have more than one assignee

Years Active: 1994-2025

Loading Chart...

25 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 12447128 - Formulations of enzalutamide (2025-10-21),

2. 11839689 - Formulations of enzalutamide (2023-12-12),

3. 10398713 - Compositions and methods for the treatment of neurodegenerative and other diseases (2019-09-03),

4. 10098843 - Compositions of 5-ethyl-2-{4-[4-(4-tetrazol-1-yl-phenoxymethyl)-thiazol-2-yl]-piperidin-1-yl}-pyrimidine (2018-10-16),

5. 9980978 - Compositions and methods for the treatment of neurodegenerative and other diseases (2018-05-29),

6. 9974798 - Compositions and methods for the treatment of neurodegenerative and other diseases (2018-05-22),

7. 9918997 - Compositions and methods for the treatment of neurodegenerative and other diseases (2018-03-20),

8. 9597339 - Compositions and methods for the treatment of neurodegenerative and other diseases (2017-03-21),

9. 9468604 - Pharmaceutical compositions of dispersions of drug and neutral polymers (2016-10-18),

10. 9457095 - Pharmaceutical compositions providing enhanced drug concentrations (2016-10-04),

11. 9241924 - Compositions of 5-ethyl-2-{4-[4-(4-tetrazol-1-yl-phenoxymethyl)-thiazol-2-yl]-piperidin-1-yl}-pyrimidine (2016-01-26),

12. 8980321 - Pharmaceutical compositions providing enhanced drug concentrations (2015-03-17),

13. 8796341 - Pharmaceutical compositions providing enhanced drug concentrations (2014-08-05),

14. 8501231 - Pharmaceutical compositions providing enhanced drug concentrations (2013-08-06),

15. 8389011 - Pharmaceutical compositions of cholesteryl ester transfer protein inhibitors (2013-03-05),

Title: Innovations by Douglas Alan Lorenz: A Journey Through Patents and Discoveries

Introduction: Douglas Alan Lorenz is a prolific inventor based in Bend, Oregon, recognized for his significant contributions to the field of pharmaceuticals. With an impressive portfolio of 24 patents, Lorenz has focused his research on advancements that address critical health issues, particularly in the areas of cancer and neurodegenerative diseases.

Latest Patents: Among his notable inventions are formulations of enzalutamide, aimed at treating hyperproliferative disorders. This breakthrough in pharmaceutical formulations highlights Lorenz's commitment to enhancing therapeutic options for patients. Additionally, he has developed innovative compositions and methods for treating neurodegenerative diseases, specifically emphasizing sulfasalazine. His latest patents disclose methods that increase the bioavailability of sulfasalazine, as well as detailing effective dosing regimens, thus providing new avenues for treatment and improved outcomes for patients suffering from these complex disorders.

Career Highlights: Lorenz has built his career at renowned organizations such as Bend Research, Inc. and Glialogix, Inc. His work at these companies has not only advanced his personal achievements but has also propelled the broader pharmaceutical industry forward. By focusing on the formulation and application of critical compounds, Lorenz has positioned himself as a vital contributor to medical science.

Collaborations: Throughout his career, Lorenz has collaborated with esteemed colleagues, including Ravi Mysore Shanker and Dwayne Thomas Friesen. These partnerships have facilitated a synergistic approach to innovation, leading to the development of effective treatments that can significantly impact patient care.

Conclusion: Douglas Alan Lorenz exemplifies the spirit of innovation and dedication to public health. His comprehensive work, marked by 24 patents, reflects a relentless pursuit of knowledge and a commitment to improving therapeutic strategies. As he continues to explore new possibilities in medicine, Lorenz remains a key figure in the world of pharmaceuticals, inspiring future inventors and promising advancements in healthcare.

This text is generated by artificial intelligence and may not be accurate.